Peripheral neurophathies induced by various chemotherapeutic agents: current state of the problem
https://doi.org/10.18821/0234-5730-2016-61-2-105-109
Abstract
This review is devoted to the problem of the neurotoxicity of chemotherapeutic agents. Peripheral neuropathy induced by chemotherapy is the specific manifestation of the neurotoxicity affecting both on the life quality of patients with oncologic pathology and possibility of the chemotherapy prescription. The toxic influences on the peripheral nervous system of chemotherapeutic agents (taxanes, epothilones, platinum compounds, vinca alkaloids, binding of growth factor inhibitors, proteasome inhibitors, immunomodulatory agents) are described. Against the background of peripheral neuropathy induced by chemotherapy there is the damage of peripheral motor, sensory and autonomous neurons, characterized by various abnormalities as follows: sensory (tingling, numbness, pain), motor (muscular delicacy, paresis) and autonomic (digestive tract motility disturbances, arrhythmia), and neuropathic pain.
About the Authors
N. T. Vatutin
M. Gorky Donetsk National Medical University;
V.K. Gusak Institute of Emergency and Reconstructive Surgery
Ukraine
Ukraine
Donetsk, 83003;
Donetsk, 83045
E. V. Sklyannaya
M. Gorky Donetsk National Medical University;
V.K. Gusak Institute of Emergency and Reconstructive Surgery
Ukraine
Ukraine
Donetsk, 83003;
Donetsk, 83045
M. A. El-Khatib
M. Gorky Donetsk National Medical University;
Center for Primary Health Care No 5
Ukraine
Ukraine
Mariam A. El-Khatib, undergraduate of department of hospital therapy M. Gorky Donetsk National Medical University
Donetsk, 83003;
Makeevka, 86114
M. V. Makarova
V.K. Gusak Institute of Emergency and Reconstructive Surgery
Ukraine
Donetsk, 83045
Ukraine
Donetsk, 83045
S. V. Starchenko
V.K. Gusak Institute of Emergency and Reconstructive Surgery
Ukraine
Donetsk, 83045
Ukraine
Donetsk, 83045
References
1. Cavaletti G., Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat. Rev. Neurol. 2010; 6(12): 657–66. doi: 10.1038/nrneurol.2010.160.
2. Bhagra A., Rao R.D. Chemotherapy-induced neuropathy. Curr. Oncol. Rep. 2007; 9(4): 290–9.
3. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol. 2004; 15(9):1439–42.
4. Chaudhry V., Rowinsky E.K., Sartorius S.E., Donehower R.C., Cornblath D.R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 1994; 35(3): 304–11.
5. von Schlippe M., Fowler C.J., Harland S.J. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumor: time course and prognosis. Br. J. Cancer. 2001; 85(6): 823–6.
6. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 2008; 358(16): 1663–71.
7. Pronk L.C., Hilkens P.H., van den Bent M.J., van Putten W.L., Stoter G., Verweij J. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs. 1998; 9(9): 759–64.
8. Sarris A.H., Hagemeister F., Romaguera J., Rodriguez M.A., McLaughlin P., Tsimberidou A.M., et al. Liposomal vincristine in relapsed nonHodgkin’s lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000; 11(1): 69–72.
9. Kelly H., Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J. Clin. Oncol. 2005; 23(20): 4553–60.
10. Stein M.E., Drumea K., Yarnitsky D., Benny A., Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am. J. Clin. Oncol. 1998; 21(3): 248–9.
11. LaPointe N.E., Morfni G., Brady S.T., Feinstein S.C., Wilson L., Jordan M.A. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013; 37(1): 231–9.
12. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubulestabilizing agents. J. Clin. Oncol. 2006; 24(10): 1633–42.
13. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer. 2008; 44(11): 1507–15.
14. Semenova A.I. Kardio- and neurotoxicity of antitumoral drugs (pathogenesis, clinic, prevention, treatment). Practical oncology. Russian journal (Prakticheskaya onkologiya). 2009; 10(3): 168–76. (in Russian)
15. Krarup-Hansen A., Rietz B., Krarup C., Heydorn K., Rorth M., Schmalbruch H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol. Appl. Neurobiol. 1999; 25(1): 29–40.
16. Smith E.M., Pang H., Cirrincione C., Fleishman S., Paskett E.D., Ahles T., et al.; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13): 1359–67. doi: 10.1001/jama.2013.2813.
17. Chaudhry V., Cornblath D.R., Polydefkis M., Ferguson A., Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J. Peripher. Nerv. Syst. 2008; 13(4): 275–82.
18. Nakata T., Yorifuji H. Morphological evidence of the inhibitory effect of taxol on the fast axonal transport. Neurosci. Res. 1999; 35(2): 113–22.
19. Theiss C., Meller K. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res. 2000; 299(2): 213–24.
20. Argyriou A.A., Koltzenburg M., Polychronopoulos P., Papapetropoulos S., Kalofonos H.P. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit. Rev. Oncol. Hematol. 2008; 66(3): 218–28.
21. Park S.B., Krishnan A.V., Lin C.S., Goldstein D., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem. 2008; 15(29): 3081–94.
22. Staff N.P., Podratz J.L., Grassner L., Bader M., Paz J., Knight A.M., et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology. 2013; 39(1): 124–31. doi: 10.1016/j.neuro.2013.09.001.
23. Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006; 27(6): 992–1002.
24. Gill J.S., Windebank A.J. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J. Clin. Invest. 1998; 101(12): 2842–50.
25. Pan Y.A., Misgeld T., Lichtman J.W., Sanes J.R. Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J. Neurosci. 2003; 23(36): 11479–88.
26. McDonald E.S., Windebank A.J. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signalling. Neurobiol. Dis. 2002; 9(2): 220–33.
27. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapyinduced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 2012; 82(1): 51–77.
28. McDonald E.S., Randon K.R., Knight A., Windebank A.J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis. 2005; 18(2): 305–13.
29. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008; 34(4): 368–77.
30. Park S., Goldstein D., Krishnan A., Lin C.S., Friedlander M.L., Cassidy J., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 2013; 63(6): 419–37. doi: 10.3322/caac.21204.
31. Russell J.W., Windebank A.J., Podratz J.L. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann. Neurol. 1994; 36(2): 221–8.
32. Cavaletti G., Cornblath D.R., Merkies I.S., Postma T.J., Rossi E., Frigeni B., et al.; CI-PeriNomS Group. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the frst validity and reliability fndings. Ann. Oncol. 2013; 24(2): 454–62. doi: 10.1093/annonc/mds329.
33. Cavaletti G., Beronio A., Reni L., Ghiglione E., Schenone A., Briani C., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology. 2004; 62(12): 2291–3.
34. Kannarkat G., Lasher E.E., Schiff D. Neurologic complications of chemotherapy agents. Curr. Opin. Neurol. 2007; 20(6): 719–25.
35. Pal P.K. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr. Clin. Neurophysiol. 1999; 39(6): 323–30.
36. Gregg R.W., Molepo J.M., Monpetit V.J., Mikael N.Z., Redmond D., Gadia M., Stewart D.J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol. 1992; 10(5): 795–803.
37. Danilov A.B. Neuropathic pain. Clinical gerontology. Russian journal (Klinicheskaya gerontologiya). 2007; 13(2): 27–36. (in Russian)
38. Dunlap B., Paice J.A. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J. Support. Oncol. 2006; 4(8): 389–99.
39. Cavaletti G., Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer. 2002; 38(14): 1832–37.
40. Sioka C., Kyritsis A.P. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol. 2009; 63(5): 761–7.
41. Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S., Rekhtina I.G., Bessmeltsev S.S., Golubeva M.E., et al. National clinical guidelines for the diagnosis and treatment of multiple myeloma. Hematology and transfusiology. Russian journal (Gematologiya i transfusiologiya). 2014; 1(Suppl. 3): 1–24. (in Russian)
42. Schroeder S., Meyer-Hamme G., Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct. Med. 2012; 30(1): 4–7.
43. Argyriou A.A., Chroni E., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., et al. Effcacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006; 67(12): 2253–5.
44. Callizot N., Andriambeloson E., Glass J., Revel M., Ferro P., Cirillo R., et al. Interleukin-6 protects against paclitaxel, cisplatin and vincristineinduced neuropathies without impairing chemotherapeutic activity. Cancer Chemother. Pharmacol. 2008; 62(6): 995–1007.
45. Savarese D.M., Savy G., Vahdat L., Wischmeyer P.E., Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. 2003; 29(6): 501–13.
46. Vahdat L., Papadopoulos K., Lange D. Reduction of paclitaxel induced peripheral neuropathy with glutamine. Clin. Cancer Res. 2001; 7(5): 1192–7.
47. Pace A., Savarese A., Picardo M., Maresca V., Pacetti U., Del Monte G., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J. Clin. Oncol. 2003; 21(5): 927–31.
48. Argyriou A.A., Chroni E., Koutras A., Ellul J., Papapetropoulos S., Katsoulas G., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005; 64(1): 26–31.
Review
For citations:
Vatutin N.T., Sklyannaya E.V., El-Khatib M.A., Makarova M.V., Starchenko S.V. Peripheral neurophathies induced by various chemotherapeutic agents: current state of the problem. Russian journal of hematology and transfusiology. 2016;61(2):105-109. (In Russ.) https://doi.org/10.18821/0234-5730-2016-61-2-105-109
Views:
743
Email this article 
